Which has preferable earnings and valuation, AAPG or EPRX?

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $574.12M 3.01 -$177.71M N/A N/A Eupraxia Pharmaceuticals N/A N/A -$38.58M -$1.05 N/A

Is AAPG or EPRX more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Eupraxia Pharmaceuticals N/A -87.56% -51.20%

Is AKTS or EPRX more profitable?

Aktis Oncology's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aktis Oncology N/A N/A N/A Eupraxia Pharmaceuticals N/A -87.56% -51.20%

Eupraxia Pharmaceuticals (EPRX) Competitors

$6.69 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$6.70 +0.00 (+0.07%)

As of 07/2/2026 06:31 PM Eastern

Compare

EPRX vs. SEPN, AAPG, HROW, ATAI, and AKTS

Should you buy Eupraxia Pharmaceuticals stock or one of its competitors? MarketBeat compares Eupraxia Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eupraxia Pharmaceuticals include Septerna (SEPN), Ascentage Pharma Group International (AAPG), Harrow (HROW), Atai Beckley (ATAI), and Aktis Oncology (AKTS). These companies are all part of the "pharmaceutical products" industry.

How does Eupraxia Pharmaceuticals compare to Septerna?

Septerna (NASDAQ:SEPN) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Septerna has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

In the previous week, Septerna had 10 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 10 mentions for Septerna and 0 mentions for Eupraxia Pharmaceuticals. Septerna's average media sentiment score of 0.15 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Septerna is being referred to more favorably in the media.

Company	Overall Sentiment
Septerna	Neutral
Eupraxia Pharmaceuticals	Neutral

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$72.26M	21.21	-$48.88M	-$0.81	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Septerna presently has a consensus price target of $45.89, suggesting a potential upside of 34.97%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 169.06%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Summary

Septerna beats Eupraxia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

Ascentage Pharma Group International currently has a consensus price target of $46.43, indicating a potential upside of 150.97%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 169.06%. Given Eupraxia Pharmaceuticals' higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$574.12M	3.01	-$177.71M	N/A	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

In the previous week, Ascentage Pharma Group International had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for Ascentage Pharma Group International and 0 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 0.00 beat Ascentage Pharma Group International's score of -0.35 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Ascentage Pharma Group International	Neutral
Eupraxia Pharmaceuticals	Neutral

Ascentage Pharma Group International has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Ascentage Pharma Group International's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Summary

Ascentage Pharma Group International beats Eupraxia Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Harrow?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, media sentiment, analyst recommendations, institutional ownership and risk.

Harrow has higher revenue and earnings than Eupraxia Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A
Harrow	$272.30M	5.85	-$5.14M	-$0.41	N/A

In the previous week, Harrow had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 2 mentions for Harrow and 0 mentions for Eupraxia Pharmaceuticals. Harrow's average media sentiment score of 0.86 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Harrow is being referred to more favorably in the news media.

Company	Overall Sentiment
Eupraxia Pharmaceuticals	Neutral
Harrow	Positive

Eupraxia Pharmaceuticals has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Harrow has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

Eupraxia Pharmaceuticals currently has a consensus target price of $18.00, indicating a potential upside of 169.06%. Harrow has a consensus target price of $69.43, indicating a potential upside of 62.44%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

72.8% of Harrow shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%
Harrow	-5.57%	19.59%	2.26%

Summary

Harrow beats Eupraxia Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

In the previous week, Atai Beckley had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 2 mentions for Atai Beckley and 0 mentions for Eupraxia Pharmaceuticals. Atai Beckley's average media sentiment score of 0.85 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Overall Sentiment
Atai Beckley	Positive
Eupraxia Pharmaceuticals	Neutral

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Atai Beckley. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$3.49M	547.82	-$660.05M	-$2.23	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Atai Beckley presently has a consensus target price of $16.00, suggesting a potential upside of 208.29%. Eupraxia Pharmaceuticals has a consensus target price of $18.00, suggesting a potential upside of 169.06%. Given Atai Beckley's stronger consensus rating and higher possible upside, analysts clearly believe Atai Beckley is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

28.4% of Atai Beckley shares are held by institutional investors. 26.8% of Atai Beckley shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Atai Beckley has a beta of 1.56, meaning that its stock price is 56% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Eupraxia Pharmaceuticals' return on equity of -87.56% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Summary

Atai Beckley beats Eupraxia Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Aktis Oncology?

Aktis Oncology (NASDAQ:AKTS) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

28.8% of Aktis Oncology shares are owned by institutional investors. 3.3% of Aktis Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aktis Oncology's return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aktis Oncology	N/A	N/A	N/A
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

In the previous week, Aktis Oncology had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 3 mentions for Aktis Oncology and 0 mentions for Eupraxia Pharmaceuticals. Aktis Oncology's average media sentiment score of 0.15 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Aktis Oncology	Neutral
Eupraxia Pharmaceuticals	Neutral

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aktis Oncology	$8.28M	204.92	-$63.73M	-$0.38	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Aktis Oncology presently has a consensus target price of $34.00, indicating a potential upside of 7.05%. Eupraxia Pharmaceuticals has a consensus target price of $18.00, indicating a potential upside of 169.06%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Summary

Aktis Oncology beats Eupraxia Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Get Eupraxia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EPRX vs. The Competition

Export

Metric	Eupraxia Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$434.98M	$3.73B	$6.96B	$12.41B
Dividend Yield	N/A	2.22%	2.68%	6.63%
P/E Ratio	-6.37	21.80	27.81	24.72
Price / Sales	N/A	318.31	553.31	110.74
Price / Cash	N/A	143.20	48.59	58.15
Price / Book	4.74	8.66	10.96	6.45
Net Income	-$38.58M	$23.81M	$3.57B	$337.01M
7 Day Performance	1.53%	3.45%	2.18%	1.36%
1 Month Performance	5.69%	8.51%	4.54%	1.68%
1 Year Performance	22.42%	62.61%	33.33%	23.97%

Eupraxia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EPRX Eupraxia Pharmaceuticals	2.056 of 5 stars	$6.69 flat	$18.00 +169.1%	+22.3%	$434.98M	N/A	N/A	29
SEPN Septerna	2.5429 of 5 stars	$34.54 -4.2%	$45.78 +32.5%	+198.2%	$1.62B	$45.95M	N/A	N/A	News Coverage Analyst Forecast Insider Trade
AAPG Ascentage Pharma Group International	4.5407 of 5 stars	$17.05 -0.2%	$46.43 +172.3%	-53.6%	$1.60B	$82.10M	N/A	600
HROW Harrow	4.4407 of 5 stars	$41.50 -2.8%	$69.43 +67.3%	+39.8%	$1.59B	$272.30M	N/A	180
ATAI Atai Beckley	3.571 of 5 stars	$4.58 +9.8%	$16.00 +249.3%	+88.7%	$1.54B	$4.09M	N/A	80	News Coverage Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EPRX) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. SEPN, AAPG, HROW, ATAI, and AKTS

How does Eupraxia Pharmaceuticals compare to Septerna?

Summary

How does Eupraxia Pharmaceuticals compare to Ascentage Pharma Group International?

Summary

How does Eupraxia Pharmaceuticals compare to Harrow?

Summary

How does Eupraxia Pharmaceuticals compare to Atai Beckley?

Summary

How does Eupraxia Pharmaceuticals compare to Aktis Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. SEPN, AAPG, HROW, ATAI, and AKTS

How does Eupraxia Pharmaceuticals compare to Septerna?

Which has more risk & volatility, SEPN or EPRX?

Does the media prefer SEPN or EPRX?

Which has better earnings and valuation, SEPN or EPRX?

Do analysts prefer SEPN or EPRX?

Is SEPN or EPRX more profitable?

Summary

How does Eupraxia Pharmaceuticals compare to Ascentage Pharma Group International?

Do analysts prefer AAPG or EPRX?

Which has preferable earnings and valuation, AAPG or EPRX?

Does the media favor AAPG or EPRX?

Which has more risk and volatility, AAPG or EPRX?

Is AAPG or EPRX more profitable?

Summary

How does Eupraxia Pharmaceuticals compare to Harrow?

Which has preferable earnings & valuation, EPRX or HROW?

Does the media prefer EPRX or HROW?

Which has more risk & volatility, EPRX or HROW?

Do analysts recommend EPRX or HROW?

Do institutionals & insiders have more ownership in EPRX or HROW?

Is EPRX or HROW more profitable?

Summary

How does Eupraxia Pharmaceuticals compare to Atai Beckley?

Does the media favor ATAI or EPRX?

Which has higher earnings & valuation, ATAI or EPRX?

Do analysts rate ATAI or EPRX?

Do insiders and institutionals hold more shares of ATAI or EPRX?

Which has more volatility & risk, ATAI or EPRX?

Is ATAI or EPRX more profitable?

Summary

How does Eupraxia Pharmaceuticals compare to Aktis Oncology?

Do insiders & institutionals believe in AKTS or EPRX?

Is AKTS or EPRX more profitable?

Does the media favor AKTS or EPRX?

Which has preferable earnings and valuation, AKTS or EPRX?

Do analysts recommend AKTS or EPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools